This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

July 8, 2025

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Modalis Therapeutics to Present MDL-101, a Muscle-Tropic AAV Vectors for the Treatment of LAMA2-CMD using CRISPR-GNDM® epigenome editing technology at 2025 SciFam

8-July-2025 TOKYO & Waltham, Mass – Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizin4g its proprietary CRISPR-GNDM® epigenome editing technology, announced that it has been invited give an oral presentation at the 2025 Scientific & Family Conference, Congenital Muscular Dystrophy/Nemaline Myopathy/Titinopathy (2025 SciFam, Aug 1-5, 2025, Philadelphia, USA). The following research results will be presented by the Company's VP, Operations and Business Development, Yosuke Nakashima. At the conference, we will present preclinical data supporting the initiation of clinical trials for MDL-101 using CRISPR-GNDM®.

Oral Presentation:

Title: Epigenetic Editing with CRISPR-GNDM®: MDL-101 is a Muscle-Tropic AAV Vectors for the Treatment of LAMA2-CMD

Date and Time: 8/4/2025, 9:00-10:00AM EST
Session Name: Genetic Therapies Agendas | SciFam Presenters | SciFam

About 2025 SciFam

SciFam is an international scientific and family conference organized by Cure CMD, focusing on rare neuromuscular disorders such as congenital muscular dystrophy (CMD), nemaline myopathy (NM), and Titinopathy (TTN-related disorders). This conference brings together researchers, clinicians, pharmaceutical and biotech industry professionals, as well as patients and families, offering a valuable opportunity to share the latest research findings and

trends in therapeutic development. It also serves as a platform to collaboratively explore ways to improve the quality of care and promote patient-centered healthcare.
At the scientific symposium where our company will present, the latest studies on disease mechanisms, preclinical and clinical trials, biomarker and natural history research, and advances in gene and molecular therapies for each condition will be introduced. Cross-disease discussions and international research collaborations will also be encouraged throughout the event. (2025 | SciFam)

About Modalis:

Modalis Therapeutics develops precision genetic medicines using epigenome editing technology. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM® technology which enables the gene/locus-specific modulation of gene expression or epigenetic editing without the need for DNA cleavage or altering DNA sequence. Headquartered in Tokyo with laboratories and facilities in Waltham Massachusetts, the company is listed on Tokyo Stock Exchange's Growth market. For additional information, visit www.modalistx.com.

For media contacts
Modalis Therapeutics
Sawako Nakamura
media@modalistx.com